MarketCap
Facebook
X
Telegram
BioNano Genomics Income Statement 2025-2011 | BNGO
Brief overview of revenue and earnings at BioNano Genomics
This overview is based on financial performance over the past five years. The revenue attributed to BioNano Genomics moved from $8.5 million to $28.5 million between the two endpoints. The total change was +235.3%, with a CAGR of approximately 27.4%. Sales grew at a rate typical of a strong expansion phase.
Gross profit changed from 2.8 million dollars to 13.2 million dollars (+375.5%). Revenue outpaced cost of revenue, allowing more sales to flow into gross profit. Gross margin moved from 32.6% to 46.3%. The margin shift points to a more favorable sales-and-cost structure.
EBITDA changed from −$37.1 million to −$23.8 million (+35.8%). EBITDA underperformed the top-line trend. EBITDA margin moved from −436% to −83.5%. The business generated more EBITDA from each unit of revenue.
The net financial result changed from −$41.1 million to −$26.4 million. The loss reduction is constructive, but the recovery is incomplete.
Overall conclusion
The financial profile remains mixed, with strengths and risks moving in different directions. The financial profile benefits from a stronger gross margin, sales growth and a stronger final result. The main areas of concern are a narrow EBITDA buffer. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement BioNano Genomics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
7.95 M | 3.55 M | 683 K | 37 M | 614 M | 1.47 B | 37.4 M | 40.8 M | - | - | - | - | - | - | - |
Shares |
5.44 M | 1.27 M | 569 K | 28.9 M | 277 M | 133 M | 34.3 M | 10.1 M | - | - | - | - | - | - | - |
Historical Prices |
1.46 | 2.79 | 1.2 | 1.28 | 2.22 | 11.1 | 1.03 | 4.1 | - | - | - | - | - | - | - |
Net Income |
-26.4 M | -112 M | -232 M | -133 M | -72.4 M | -41.1 M | -29.8 M | -18.5 M | -23.4 M | -18.8 M | - | - | - | - | - |
Revenue |
28.5 M | 30.8 M | 36.1 M | 27.8 M | 18 M | 8.5 M | 10.1 M | 12 M | 9.51 M | 6.79 M | - | - | - | - | - |
Cost of Revenue |
15.3 M | 30.4 M | 26.6 M | 21.9 M | 14.1 M | 5.73 M | 6.77 M | 8.71 M | 6.03 M | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | 2.77 M | 3.36 M | 3.29 M | 3.47 M | 3.21 M | - | - | - | - | - |
Operating Income |
-33.3 M | -104 M | -215 M | -132 M | -77.1 M | -38.6 M | -25.9 M | -20.4 M | -23.2 M | - | - | - | - | - | - |
Interest Expense |
5.9 M | -10.1 M | 5.12 M | 298 K | 927 K | 2.52 M | 2.29 M | 1.38 M | 591 K | - | - | - | - | - | - |
EBITDA |
-23.8 M | -90 M | -202 M | -122 M | -73.8 M | -37.1 M | -24.7 M | -19.1 M | -21.1 M | -20.1 M | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | 41.3 M | 29.2 M | 23.7 M | 26.1 M | 24.4 M | - | - | - | - | - |
General and Administrative Expenses |
35.2 M | 51.9 M | 92.8 M | 88.6 M | 58.5 M | 31.1 M | 20.2 M | 14.2 M | 14.1 M | 13 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement BioNano Genomics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
11 M | 5.34 M | 3.44 M | 2.69 M | 1.87 M | 1.43 M | 1.13 M | 879 K | 45.8 M | 35 M | 31.5 M | 30.2 M | 29.7 M | 29 M | 28.6 M | 285 M | 290 M | 280 M | 279 M | 264 M | 190 M | 133 M | 90.9 M | 35.6 M | 34.3 M | 10.9 M | 10.9 M | 10.2 M | 10.1 M | 7.78 M | 3.36 M | 3.32 M | 77.3 K | 2.92 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-8.3 M | -8.5 M | -6.86 M | -3.1 M | - | -44.2 M | -16.2 M | -31.4 M | - | -113 M | -38.9 M | -37.1 M | - | -31.8 M | -32.2 M | -30 M | - | -20.8 M | -18.8 M | -9.95 M | - | -10.8 M | -8.07 M | -10.5 M | -7.9 M | -6.4 M | -6.4 M | -7.9 M | -6.41 M | -4.93 M | -3.31 M | -3.85 M | 5.92 M | -23.4 M | 6.67 M | 5.69 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
6.69 M | 7.37 M | 6.73 M | 6.46 M | - | 6.07 M | 7.77 M | 8.77 M | - | 9.32 M | 8.66 M | 7.42 M | - | 7.22 M | 6.67 M | 5.7 M | - | 4.66 M | 3.86 M | 3.17 M | - | 2.2 M | 1.18 M | 1.14 M | 2.79 M | 3.31 M | 2.18 M | 1.85 M | 4.01 M | 2.83 M | 3.39 M | 1.77 M | 2.85 M | 2.74 M | 2.2 M | 1.72 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
3.44 M | 4 M | 3.26 M | 3.52 M | - | 14.5 M | 5.19 M | 5.94 M | - | 6.57 M | 6.35 M | 5.34 M | - | 5.41 M | 5.2 M | 4.84 M | - | 3.5 M | 2.42 M | 2.12 M | - | 1.46 M | 603 K | 856 K | 1.69 M | 2.38 M | 1.56 M | 1.15 M | 2.99 M | 3.07 M | 1.81 M | 841 K | 1.5 M | 1.69 M | 1.64 M | 1.21 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-7.9 M | -8.54 M | -7.8 M | -8.46 M | - | -43.9 M | -17 M | -31.1 M | - | -113 M | -39.2 M | -37.8 M | - | -32.1 M | -32.1 M | -29.9 M | - | -20.7 M | -16.5 M | -11.2 M | - | -10.2 M | -7.44 M | -9.76 M | - | -5.68 M | -6.84 M | -6.18 M | - | -5.97 M | -4.01 M | -4.34 M | - | -5.03 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-619 K | -219 K | 676 K | 5.08 M | - | -697 K | 363 K | -1.36 M | - | -45 K | -330 K | 76 K | - | 73 K | 74 K | 77 K | - | 2 K | 210 K | 603 K | - | 589 K | 561 K | 761 K | - | 578 K | 645 K | 273 K | - | 404 K | 408 K | 302 K | - | 145 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-5.59 M | - | - | -6.03 M | - | - | - | -28.1 M | - | - | - | -34.7 M | - | -25.3 M | -32.1 M | -27.7 M | - | -19.2 M | -16.5 M | -10.7 M | - | -9.32 M | -6.84 M | -9.47 M | - | -5.41 M | -6.58 M | -5.92 M | - | -5.58 M | -3.63 M | -3.94 M | - | -4.79 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
8.01 M | 9.06 M | 8.35 M | 9.03 M | - | 9.46 M | 11.6 M | 19.1 M | - | 24.9 M | 26.9 M | 26 M | - | 21.2 M | 21.8 M | 20.3 M | - | 15.3 M | 13.8 M | 9.53 M | - | 8.66 M | 5.61 M | 7.37 M | - | 4.45 M | 5.06 M | 4.79 M | - | 3.22 M | 3.49 M | 2.9 M | - | 3.12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company BioNano Genomics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Germany
Canada
Niderland
Britain
Israel
China
Australia
Irlanda
Schweiz
